Daniel Carrizosa, MD, MS

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.